UNSPSC 51343825: Glecaprevir/Pibrentasvir

Glecaprevir/pibrentasvir (G/P)is a fixed-dose combination medication used to treat hepatitis C.

UNSPSC 51343825 Glecaprevir/Pibrentasvir is a Commodity code that encompasses pharmaceutical procurement by state and local health agencies, long-term care facilities, and emergency medical services systems. Recent state and local opportunities under this code show little direct activity aligned with the antiviral medication itself; instead, the tagged opportunities span a broader pharmaceutical and drug-related procurement landscape that includes pharmacy benefits management, emergency drug distribution, and forensic drug analysis. The actual buying under the code's nominal scope appears limited, with recent solicitations predominantly addressing pharmacy services delivery systems, naloxone distribution infrastructure, and ancillary pharmaceutical infrastructure rather than acquisition of the specific antiviral drug product.

Geographic activity spans Florida (Collier County, Dane County in Wisconsin, Clay County, Palm Bay, Seminole County, Pinellas County), the District of Columbia, Oregon (Washington County), Kentucky (City of Owensboro), California (San Mateo County), Arizona (Tucson Fire Department), Texas (West Texas Centers, Bernalillo County), and a broader multistate mix. Issuing bodies include county governments, cities, fire departments, behavioral health authorities, and forensic laboratories. Representative recent opportunities show minimal direct pharmaceutical procurement: Dane County issued an RFP for comprehensive pharmaceutical services to Badger Prairie Health Care Center (RFP 2026RFP061PR, due October 22, 2026) covering medication delivery, dispensing, and quality assurance with a five-year term and $125,000 annual funding; the City of Tucson Fire Department requested proposals for BLS/ALS pharmaceuticals and supplies with VendNovation vending machines (RFP 260217, due June 24, 2026, federally funded through ARPA and HUD grants with Section 3 labor requirements); and West Texas Centers solicited pharmacy services for over 7,000 individuals across 35 sites in 23 counties (RFP RX1001, due August 21, 2026). The code shows limited recent procurement activity directly tied to Glecaprevir/Pibrentasvir or comparable antiviral drug products; most tagged opportunities address pharmaceutical delivery infrastructure, emergency medical supply distribution, and pharmacy benefit management rather than the medication class itself.